Table 3

Univariate and multivariate hazard ratios for recurrence of MI

	Univariate		Multivariate†
Outcome predictor	RR	95% CI	RR	95% CI
p<0.05; *p<0.01; †for 1419 patients.
ACE, angiotensin converting enzyme; CI, confidence interval; RR, relative risk.
Adherence to statins (%)
0 (n=5163)	1.00		1.00
<39 (n=67)	0.55	0.25 to 1.22	0.59	0.22 to 1.59
40–79 (n=88)	0.38*	0.16 to 0.90	0.51	0.19 to 1.35
80–100 (n=272)	0.35**	0.20 to 0.60	0.19**	0.08 to 0.47
Statin daily dose (high v 10 mg)	0.47	0.18–1.25	0.42	0.06 to 3.26
Lipid lowering drug use before MI (yes v no)	0.87	0.45–1.87	2.58**	1.19 to 5.60
Other lipid lowing drugs	0.45*	0.26 to 0.78	0.49	0.22 to 1.14
β Blockers	0.67*	0.57 to 0.79	0.65*	0.42 to 1.00
Antiplatelet + aspirin	0.92	0.80 to 1.07	0.93	0.58 to 1.51
Diuretics	0.92	0.80 to 1.07	0.58*	0.36 to 0.92
ACE inhibitor	0.67**	0.55 to 0.82	0.80	0.49 to 1.31
Other antihypertensive drugs	0.63	0.35 to 1.15	0.57	0.20 to 1.63
Nitrates	0.91	0.79 to 1.06	0.83	0.51 to 1.36
Calcium channel blocker	0.95	0.82 to 1.11	1.19	0.76 to 1.87
Number of types of CV drugs used
0	1.00		1.00
1–2	1.25	1.01 to 1.56	1.93	0.90 to 4.15
3–4	0.94	0.77 to 1.15	1.40	0.41 to 4.85
≥5	0.63**	0.48 to 0.83	1.89	0.33 to 10.97
Sex (male v female)	0.88	0.76 to 1.02	1.13	0.81 to 1.56
Age (years)
<50	1.00		1.00
50–59	1.57*	1.06 to 2.34	1.27	0.67 to 2.38
60–69	1.94*	1.34 to 2.82	2.14*	1.17 to 3.92
70–79	2.44**	1.69 to 3.54	2.72**	1.43 to 5.17
≥80	3.19**	2.18 to 4.67	3.99**	1.79 to 8.87
Socioeconomic deprivation
1–2 (least deprived)	1.00		1.00
3–4	1.01	0.84 to 1.22	1.01	0.69 to 1.49
5–7 (most deprived)	1.25*	1.03 to 1.52	1.52*	1.04 to 2.21
Baseline cholesterol	0.99	0.90 to 1.10	1.07	0.96 to 1.20
Diabetes mellitus	2.16**	1.69 to 2.76	2.16**	1.38 to 3.37
Year 1994 (after v before)	0.80	0.57 to 1.02	0.61	0.30 to 1.22
Other hospitalisation after MI (excluding surgical admission)	1.33	0.93 to 1.88	1.69	0.91 to 3.13